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Background: Idiopathic interstitial pneumonias such as idiopathic pulmonary fibrosis or fibrotic nonspecific
interstitial pneumonia are irreversible progressive pulmonary diseases that often have fatal outcomes. Although the
etiology of idiopathic interstitial pneumonias is not yet fully understood, anti-fibrotic and anti-inflammatory agents
have shown limited therapeutic effectiveness. Reactive oxygen species and their cytotoxic effects on the lung
epithelial cells have been reported to participate in the pathophysiology of the disease. Because superoxide
dismutase catalyzes the detoxification of reactive oxygen species, we developed lecithinized superoxide dismutase
for the treatment of patients with idiopathic interstitial pneumonias.
Methods: A multicenter, randomized, placebo-controlled trial was conducted as a pilot study to investigate the
safety and effectiveness of 40 or 80 mg lecithinized superoxide dismutase in patients with progressive idiopathic
interstitial pneumonias who presented with either idiopathic pulmonary fibrosis or corticosteroid-resistant fibrotic
nonspecific interstitial pneumonia and showed arterial oxygen tension compatible with stage III or IV on the
Japanese severity grading scale for idiopathic interstitial pneumonias. Before and following infusion of lecithinized
superoxide dismutase for 28 days, the primary endpoint of forced vital capacity and the secondary endpoints of
lactate dehydrogenase, surfactant protein-A, surfactant protein-D and Krebs von den Lungen-6 levels were
measured in the serum.
Results: The primary endpoint of forced vital capacity did not improve significantly in the lecithinized superoxide
dismutase groups in comparison with the placebo group. The secondary endpoints of lactate dehydrogenase and
surfactant protein-A levels were significantly attenuated by 28 days in the higher-dose (80 mg) group. However,
these changes returned to the baseline levels by 56 days after the cessation of lecithinized superoxide dismutase.
Adverse events and mortality in the drug-treated groups did not differ from those in the placebo group.
Conclusions: Treatment with lecithinized superoxide dismutase is safe and improves the levels of serum markers
such as lactate dehydrogenase and surfactant protein-A in patients with advanced idiopathic interstitial pneumonias
with severe respiratory dysfunction. Considering the results of the current study, further investigations into the
effects and treatment potential of long-term administration of lecithinized superoxide dismutase may be warranted.
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Idiopathic interstitial pneumonia (IIP) is a broad term
comprising a set of lung diseases, including idiopathic
pulmonary fibrosis (IPF), nonspecific interstitial pneu-
monia (NSIP), cryptogenic organizing pneumonia (COP)
and others [1]. While COP has relatively good prognosis
among IIPs, IPF and fibrotic NSIP progress irreversibly
with most patients eventually dying because of respira-
tory insufficiency [2,3]. With efforts to develop new
treatments, several promising drugs, such as pirfenidone
have emerged.
Although the etiology of IIP is not yet fully under-
stood, recent studies have suggested that it is triggered
by lung injury and subsequent inflammation. Reactive
oxygen species (ROS) and their effects on lung epithelial
cells are reported to be involved in the pathophysiology
of IIPs [4]. ROS are released from activated leukocytes
in response to environmental factors such as air pollutants
or cigarette smoke, resulting in further lung injury and
inflammation. Furthermore, it has been reported that
lung epithelial cells from IPF patients generate higher
levels of ROS than those from controls [5]. One study
showed that genetic modulation that increased pulmon-
ary levels of ROS resulted in stimulation of bleomycin-
induced pulmonary fibrosis [6]. The cellular redox state,
determined by the balance between ROS and antioxidant
molecules, is considered important in the pathogenesis of
IIPs. Therefore, antioxidant molecules are receiving con-
siderable attention as therapeutic candidates for the treat-
ment of IPF.
Superoxide dismutase (SOD) catalyzes the dismutation
of superoxide anion to hydrogen peroxide, which is sub-
sequently detoxified to oxygen and water by catalase or
glutathione peroxidase [7]. A decreased level of SOD was
observed in IPF patients, suggesting that supplementation
with SOD could be of therapeutic benefit for patients with
IPF [8]. SOD has low affinity to cell or tissue membranes
and a half-life of only a few minutes. PC-SOD, a lecithi-
nized human Cu, Zn-superoxide dismutase (SOD) prepar-
ation, was developed on the basis of the concepts first
proposed by Dr Mizushima Y and colleagues in Japan in
the early 1990s [9]. As a result of lecithinization, PC-SOD
exerts a high affinity for cell and tissue membranes, main-
taining prolonged pharmacological activities in vivo, andameliorated fibrosis in bleomycin-induced pneumonitis in
mice [10]. In humans, the effectiveness and safety of intra-
venous 40 mg or 80 mg PC-SOD have been demonstrated
through administration to patients with ulcerative colitis,
in which the involvement of oxidative stress caused by
reactive oxygen species is implicated [11].
In this study, we conducted a multicenter, double-blind,
placebo-controlled clinical trial of PC-SOD (midismase)
to investigate the safety and effectiveness of this agent
in patients with advanced IIPs diagnosed as either IPF
or corticosteroid-resistant fibrotic nonspecific intersti-
tial pneumonia (srf-NSIP).
Methods
A multicenter, double-blind, placebo-controlled clinical
trial was conducted at 10 medical institutions in Japan
for patients with IPF or srf-NSIP. Patients were in agree-
ment with the study procedures and provided informed
written consent. The study protocol was approved by the
institutional review boards (IRBs) of each participating
medical institution (Tohoku University Hospital IRB, Jichi
Medical University Hospital IRB, Toho University Sakura
Medical Center IRB, Teikyo University Hospital IRB,
Nippon Medical School Hospital IRB, JR Tokyo General
Hospital IRB, Tosei General Hospital IRB, Tenri Hospital
IRB, National Hospital Organization Kinki-Chuo Chest
Medical Center IRB, and Saiseikai Kumamoto Hospital
IRB). Ongoing safety results were reviewed by an Inde-
pendent Data Monitoring Committee (IDMC) at 2-month
intervals. This clinical trial was registered in the University
hospital Medical Information Network (UMIN) clinical
trials registry (trial no. 000000752) in June 2007.
Patients with IPF or srf-NSIP as diagnosed by clinical
symptoms, chest radiography examination, and high-
resolution computed tomography (HRCT) scans were
included in this study. Patients with srf-NSIP were de-
fined as having a history of steroid use at doses above
10 mg per day administered for longer than 3 months.
In Japan, classification of the severity of IIPs (stages I-IV)
has been used for decisions regarding subsidization of
medical care. The stages of severity of IIPs are as follows:
stage I (partial arterial oxygen concentration ≧80 mmHg
at rest), stage II (partial arterial oxygen concentration of
70–80 mmHg at rest), stage III (partial arterial oxygen
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(partial arterial oxygen concentration <60 mmHg at
rest). Severity should be increased by 1 stage for pa-
tients with stage II or stage III disease, if arterial oxygen
saturation during a 6-min walk distance test is <90%
[12]. This classification is highly correlated with IPF
survival [13]. Therefore, eligible patients with stage III
or stage IV disease were recruited for this study. Although
histopathological diagnosis of NSIP was facilitated by a
surgical lung biopsy or transbronchial lung biopsy, IPF
was clinically diagnosed in accordance with the ATS/ERS
consensus statement [14].
Patients were excluded from this study for the following
reasons: complications of asthma, chronic obstructive pul-
monary disease, or lung infection; initiation or change in
the usage and dosage of corticosteroid treatment in the
past 4 weeks; and initiation or alteration in immunosup-
pressant treatment (ciclosporin, azathioprine, and cyclo-
phosphamide) in the past 2 months.
Patients previously receiving corticosteroids, immuno-
suppressants, or oxygen inhalation therapy for IIPs were
allowed to continue taking these treatments, provided that
they did not alter the dosage and/or schedule, whereas no
limitation was placed on receiving concomitant therapies
for disease complications.
Enrolled patients were equally randomized at the Regis-
tration Center by dynamic allocation using a minimization
method based on sex, disease severity, and medical in-
stitution, to receive either placebo or PC-SOD (40 mg
or 80 mg). Each vial of investigational product was
masked to ensure double-blind administration. Test
agents were intravenously administered by drip infusion
over approximately 1 h once daily in the morning for 28
successive days in an inpatient setting.
Patients underwent a forced vital capacity (FVC) test
as the primary outcome measurement at baseline,
28 days, and 56 days after starting administration of the
investigational drug. Secondary outcome measurements,
including percent vital capacity (%VC), total lung capacity
(TLC), diffusing capacity for carbon monoxide (%DLCO),
and arterial oxygen saturation (SpO2), were assessed as
indicators of lung function at baseline and on post-
treatment days 28 and 56. Serum levels of Krebs von den
Lungen-6 (KL-6), surfactant protein (SP)-D, SP-A, and
lactate dehydrogenase (LDH) were assessed as markers of
interstitial pneumonia at baseline and on days 14, 28, 42,
and 56. Each patient's impression of the treatment was
assessed by the Borg scale [15].
All items for primary and secondary outcome mea-
surements, except %DLCO, were rated as follows:
“improvement”, if improved by >10%; “decline”, if
declined by >10%; and unchanged. %DLCO was rated
similarly, except that “improvement” was defined as im-
proved by >5%.All adverse events occurring during the study were
thoroughly investigated and their treatment, outcome,
and causal relation with the investigational drug were re-
corded in case report forms. Serious adverse events were
defined as fatal, life-threatening, requiring hospitalization
or extension of hospitalization, acquisition of permanently
lasting or remarkable impairment or dysfunction, or in-
duction of congenital anomaly.
Data on all adverse events, including clinical symp-
toms and findings, date of incidence, severity level, ser-
iousness, treatment, outcome, and causal relations with
the study drug were recorded on case report forms. All
adverse events were followed until the lead investigator
or secondary investigator concluded that they had sub-
sided or become medically unproblematic. Follow-up data
for adverse events were recorded.
Statistical analysis
The full analysis set (FAS), used for the assessment of
efficacy, comprised all patients who completed ≧70% of
the investigational drug administration schedule. Safety
was investigated in patients who took the investigational
drug at least once. Changes in each assessment item
during the follow-up period were investigated by a one-
way analysis of variance (ANOVA), whereas comparison
among the treatment groups was conducted by the least
significant difference (LSD) method. Missing data values
were replaced by the last observed value of that variable.
A significance level of 5% was set for all data.
Results
Patients
Between June and September 2007, a total of 55 patients
(diagnosis of IPF, n = 47; srf-NSIP, n = 8) were randomly
allocated to receive either a placebo (n = 18), 40 mg of
PC-SOD (n = 18), or 80 mg of PC-SOD (n = 19). Of
these, 5 patients (9.1%) whose FVC was not determined
at baseline or who were not treated with the test agents
for ≧20 days were excluded. Therefore, 16 patients receiv-
ing the placebo, 17 patients receiving 40 mg of PC-SOD,
and 17 patients receiving 80 mg PC-SOD were analyzed as
FAS (Figure 1). The demographic characteristics of these
patients were not significantly different among treatment
groups, with the exception of disease category (Table 1).
Although some patients received corticosteroids and
immunosuppressive agents, the frequency of usage was
not different between the groups.
No significant differences in mean change of FVC (the
primary efficacy endpoint) from baseline, pulmonary
function tests (such as %VC, TLC, %DLCO, and SpO2 at
rest), and subjects’ impressions (Borg scale) were detected
among the 3 groups on days 28 and 56 (Table 2). Con-
versely, significant improvements of LDH and SP-A were
observed in the treatment group receiving the higher-dose
Figure 1 Disposition of patients. A total of 55 patients diagnosed with idiopathic pulmonary fibrosis (n = 47) or corticosteroid-resistant fibrotic
nonspecific interstitial pneumonia (n = 8) were randomly allocated to receive either a placebo (n = 18), 40 mg of lecithinized superoxide
dismutase (PC-SOD) (n = 18), or 80 mg of PC-SOD (n = 19). Of these, 5 patients whose forced vital capacity (FVC) was not determined at baseline
or who were not treated with the test agent for ≧20 days were excluded. Therefore, 50 patients were analyzed as a full analysis set. Among these
patients, one patient who was not treated by PC-SOD and 11 patients who undertook bronchoalveolar lavage fluid (BAL) analysis were excluded
from the per protocol set. While not prohibited in the initial study protocol, performing BAL analysis during the study period was proscribed by
the independent data monitoring committee to secure the safety of patients. Therefore, 17 patients (30.9%) were excluded from the study
population.
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(Table 2). Furthermore, these changes were observed in a
dose-dependent manner (Table 2). The time-course of
changes in interstitial pneumonia markers for each group
is depicted in Figure 2. Both LDH and SP-A returned
to baseline levels by 56 days after discontinuation of
PC-SOD.
Safety
Incidence rates of adverse events (total and those associ-
ated with the study medication), a detailed list of serious
adverse events, and mortality numbers and rates are
displayed in Table 3. Incidence rates of adverse events in
the placebo, 40 mg PC-SOD, and 80 mg PC-SOD groups
were 83.3, 88.9, and 100.0%, respectively. Those associated
directly with PC-SOD were 44.4% for 40 mg PC-SOD and
73.7% for 80 mg PC-SOD. No significant differences were
detected among the groups in the incidence rates of ad-
verse events and those associated with PC-SOD. Further-
more, the incidence of serious adverse events was not
significantly different among the 3 groups (Table 3).
Eight patients died during the study period due to
concomitant diseases or acute exacerbation (AE) of IIPs
(placebo group, n = 3; 40 mg PC-SOD, n = 2; 80 mg PC-
SOD, n = 3) (Table 3). No significant differences in mortal-
ity rate were observed among the 3 groups. The cause of
death in all cases was AE of interstitial pneumonia (IP),
with the exception of one fatality in the high-dose group.
AEs of IP occurred from days 22 to 71 after the start of
PC-SOD.
Discussion
Among IIPs, there are devastating diseases such as IPF
and f-NSIP that particularly deteriorate respiratoryfunction [16,17]. The pathological process advances
gradually and exacerbates, usually resulting in death due
to respiratory dysfunction. Thus, therapeutic methods that
contribute to ameliorating the prognosis are urgently
required.
The primary aim of the present study was to confirm
the safety of PC-SOD when used for the treatment of
advanced-stage IPF and srf-NSIP. We observed no signifi-
cant difference in the occurrence of adverse events, and
serious adverse events were similar among the active and
control groups. During the study, 8 patients died as a re-
sult of progression of their original disease or complica-
tions. However, no significant difference was detected in
the mortality rate among the 3 groups.
Among the causes of death, AE of IP was most fre-
quently observed, and all those who died were patients
with IPF. Because drugs such as anti-cancer or anti-tumor
necrosis factor-α may exacerbate pre-existing IP [18,19],
there was concern that administration of PC-SOD would
induce AE of IP. Although AE of IP occurred during the
study period, the frequency was similar between the 3
groups. Therefore, it is unlikely that PC-SOD accelerated
the exacerbation of IP. Moreover, we previously adminis-
tered 80 mg of PC-SOD repeatedly for 7 days in a phase I
study conducted in healthy volunteers, and safely repeated
the dosing over 14 days in a phase II study performed in
patients with ulcerative colitis who did not show acute
lung injury [11]. Thus, there are no particular safety con-
cerns regarding the use of 40–80 mg PC-SOD in patients
with IPF and srf-NSIP.
In the current study, 7 out of 55 (12.3%) patients expe-
rienced AE of IP. This frequency appears to be higher
than that in a previous study in which the 2-yr frequency
of AE of IP was reported to be 9.6% [20]. We assumed








Disease category, n (%)
IPF 16 (100.0) 12 (70.6) 16 (94.1) 0.037
NSIP 0 (0.0) 5 (29.4) 1 (5.9)
Sex, n (%)
Male 14 (87.5) 14 (82.4) 14 (82.4) 1.000#
Female 2 (12.5) 3 (17.6) 3 (17.6)
Medical history, n (%)
No 3 (18.8) 3 (17.6) 6 (35.3) 0.537#
Yes 13 (81.3) 14 (82.4) 11 (64.7)
Concomitant disease, n (%)
No 0 (0.0) 0 (0.0) 1 (5.9) 1.000#
Yes 16 (100.0) 17 (100.0) 16 (94.1)
Corticosteroid use§, n (%)
No 9 (56.2) 5 (29.4) 9 (52.9) 0.286†
Yes 7 (43.8) 12 (70.6) 8 (47.1)
Immunosuppressant use¶, n (%)
No 10 (62.5) 10 (58.8) 12 (70.6) 0.900†
Yes 6 (37.5) 7 (41.2) 5 (29.4)
Age (years) 66.8 ± 8.1 66.4 ± 7.0 67.4 ± 9.0 0.943††
Body weight (kg) 65.2 ± 10.6 61.9 ± 10.7 62.1 ± 10.5 0.608††
FVC (mL) 2158 ± 706 1819 ± 481 1857 ± 471 0.177††
%VC (%) 68.2 ± 17.3 61.5 ± 12.7 59.6 ± 11.2 0.197††
TLC (mL) 3113 ± 825 2834 ± 719 2842 ± 667 0.501††
%DLCO (%) 32.67 ± 7.95 32.01 ± 16.08 34.88 ± 15.45 0.827††
SpO2 (%) 94.94 ± 2.21 95.06 ± 2.14 93.76 ± 2.97 0.254
††
KL-6 (U/mL) 1312.8 ± 473.0 1656.8 ± 932.5 1348.1 ± 555.9 0.290††
SP-D (ng/mL) 300.6 ± 200.49 272.53 ± 124.18 314.84 ± 301.20 0.852††
SP-A (ng/mL) 90.34 ± 46.99 92.41 ± 43.36 90.58 ± 38.49 0.988††
LDH (IU/L) 245.6 ± 63.6 241.8 ± 41.0 287.2 ± 88.4 0.104††
Borg scale 3.2 ± 2.1 3.5 ± 2.6 2.8 ± 2.2 0.672††
*Parameters other than sex, medical history, concomitant disease, corticosteroid use, and immunosuppressant use are expressed as mean ± SD.
#Fisher’s exact test.
§> 5 mg/day prednisone.
†Pearson’s χ2 test.
¶An immunosuppressant was chosen from ciclosporin, cyclophosphamide or azathioprine.
††One-way analysis of variance (ANOVA).
Definition of abbreviations: IPF = idiopathic pulmonary fibrosis; NSIP = nonspecific interstitial pneumonia, PC-SOD = lecithinized superoxide dismutase; FVC = forced
vital capacity; VC = vital capacity; TLC = total lung capacity; DLCO = diffusing capacity for carbon monoxide; KL-6 = Krebs von den Lungen-6; SP-D = surfactant
protein-D; SP-A = surfactant protein-A; LDH = lactate dehydrogenase.
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due to the current inclusion criteria which aimed to
recruit more severely ill patients with stage III or IV
disease, as classified on the Japanese severity scale of
IIPs. This inclusion criteria was considered appropriate
because PC-SOD was administered to patients intraven-
ously, requiring the patients to be hospitalized during the
trial period. Moreover, patients with severe disease withrelatively prominent clinical symptoms were deemed
suitable for the evaluation of the efficacy and safety of
the investigational product.
Although changes in FVC was the primary outcome
measurement in this study, there was no significant
difference between the study drug groups and the placebo
group. Changes in FVC or VC are considered to be im-
portant indicators in prognosis of IPF [21-24], and both
Table 2 Changes in primary and secondary efficacy variables: days 28 and 56
Amount of change
Parameter Placebo (n = 16) 40 mg PC-SOD (n = 17) 80 mg PC-SOD (n = 17)
Day 28
FVC, % 2.068 ± 6.539 −2.567 ± 12.175 2.927 ± 11.822
LDH, % 0.0 ± 11.3 −0.1 ± 22.1 −12.4 ± 11.0*
SP-A, % −1.9 ± 20.8 −10.9 ± 22.3 −21.2 ± 16.9†
SP-D, % −5.1 ± 24.4 −10.9 ± 31.5 −8.6 ± 45.6
KL-6, % −4.7 ± 14.4 −7.3 ± 16.8 −8.0 ± 18.5
Borg scale −0.19 ± 0.77 0.26 ± 1.94 0.15 ± 1.41
Day 56
FVC, % 1.127 ± 7.951 −1.993 ± 13.517 0.606 ± 13.716
LDH, % 1.5 ± 14.4 3.6 ± 24.8 2.4 ± 19.3
SP-A, % 3.1 ± 18.1 −1.3 ± 23.8 3.4 ± 19.9
SP-D, % 7.6 ± 41.4 −7.8 ± 35.5 10.9 ± 66.1
KL-6, % −2.7 ± 17.9 −2.8 ± 18.6 −0.7 ± 21.1
Borg scale −0.06 ± 1.08 0.06 ± 1.08 0.97 ± 2.24
Mean ± SD. *P < 0.05 vs. placebo, †P < 0.01 vs. placebo.
Definition of abbreviations: PC-SOD = lecithinized superoxide dismutase; FVC = forced vital capacity; LDH = lactate dehydrogenase; SP-A = surfactant protein-A;
SP-D = surfactant protein-D; KL-6 = Krebs von den Lungen-6.
Figure 2 Time-course of changes in idiopathic interstitial pneumonia markers. Treatment with the investigational drug was conducted
from days 1 to 28. Diamonds, squares, and circles in panels A, B, C, and D indicate the placebo, 40 mg lecithinized superoxide dismutase (PC-SOD),
and 80 mg PC-SOD, respectively. (A) Serum lactate dehydrogenase (LDH) significantly improved compared to the placebo in the 80 mg PC-SOD group
on day 28 (†P < 0.05). Serum LDH returned to the baseline level within 56 days after the discontinuation of PC-SOD. (B) Serum surfactant protein (SP)-A
significantly improved compared to the placebo in the 80 mg PC-SOD group on day 28 (†P < 0.05). Serum SP-A returned to the baseline level within
56 days after the discontinuation of PC-SOD. (C) Serum SP-D did not improve with PC-SOD treatment. (D) Serum Krebs von den Lungen-6 (KL-6) did
not improve with PC-SOD treatment. Ordinate: Relative values of serum levels of LDH (A), SP-A (B), SP-D (C), and KL-6 (D) to their baseline levels
(arbitrarily set as unity). Abscissa: Time (days) after the study was started.
Kamio et al. BMC Pulmonary Medicine 2014, 14:86 Page 6 of 9
http://www.biomedcentral.com/1471-2466/14/86
Table 3 Incidence rates of total adverse events and adverse events associated with the study medication, list of





P-value* 80 mg PC-SOD
(n = 19)
P-value*
Number of patients with at least 1 adverse event (%) 15 (83.3) 16 (88.9) 1.000 19 (100.0) 0.105
Number of patients with at least 1 adverse event
directly associated with PC-SOD (%)
— 8 (44.4) — 14 (73.7) 0.184†
Serious adverse event, n (%)
Myocardial ischemia 0 (0.0) 1 (5.6) 1.000 0 (0.0) —
Pneumonia 1 (5.6) 0 (0.0) — 2 (10.5) 1.000
Pneumothorax 0 (0.0) 0 (0.0) — 2 (10.5) 1.000
Pulmonary embolism 0 (0.0) 1 (5.6) 1.000 0 (0.0) —
Interstitial lung disease¶ 3 (16.7) 3 (16.7) 1.000 3 (15.8) 1.000
Pneumomediastinum 0 (0.0) 0 (0.0) — 1 (5.3) 1.000
Febrile disorders 1 (5.6) 1 (5.6) 1.000 0 (0.0) —
Acute respiratory failure 0 (0.0) 0 (0.0) — 1 (5.3) 1.000
Mortality, n (%) 3 (16.7) 2 (11.1) 2 (15.8)
*Fisher’s direct probability test vs. placebo.
†Fisher’s direct probability test vs. 40 mg PC-SOD.
¶Nine patients were required to stay in the hospital over the study period because of progression of interstitial lung disease.
Definition of abbreviation: PC-SOD = lecithinized superoxide dismutase.
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anti-fibrotic properties, have been reported to ameliorate
the decline of VC and FVC, respectively [25-27]. Most of
these studies see changes in FVC within 6 to 12 months.
The 56-day observation period in this study appears to be
too short to detect a significant difference. Considering
this, longer-term continuous administration of the study
drug is required for future study.
Despite the absence of significant changes in FVC,
80 mg PC-SOD significantly improved the levels of bio-
logical markers such as serum LDH and SP-A, compared
to the levels in the placebo group at 28 days after drug
administration. Both LDH and SP-A have been reported
to increase in patients with IIPs [28,29]. These increase
in parallel with an extended radiological display of a
ground-glass appearance, and are important as parame-
ters to predict early mortality of IPF patients [30,31].
Although LDH is a marker that lacks organ specificity,
baseline levels in our IIP patients were higher than
240 IU/L, suggesting that the LDH was released from
pulmonary tissue cells. Thus, the decrease in the serum
LDH level following injection of PC-SOD was inter-
preted as an indication of the drug’s favorable effects on
pulmonary tissue cells. In contrast to LDH, SP-A is se-
creted mainly from type II pneumocytes, and the at-
tenuation of SP-A after the administration of PC-SOD
appears to reflect the essential effect of this agent, al-
though improvement of survival rate was not observed
in the current study. It is important to note that both
LDH and SP-A reverted to original levels by termin-
ation of the treatment on day 56. These results suggestthat continuous treatment with PC-SOD may be required
to elicit a clinical benefit.
In this study, PC-SOD was administered intravenously
for 28 consecutive days. However, in consideration of the
quality of life of patients, daily intravenous administration
of the drug is not an optimal treatment approach. To
resolve this problem, we have developed a method of
PC-SOD administration by inhalation and have demon-
strated that this procedure is effective against bleomycin-
induced pulmonary fibrosis in mice [32,33]. Future studies
of PC-SOD administered by inhalation for IPF patients are
planned.
We performed the analysis using FAS excluding patients
whose baseline FVC was not determined or who were not
treated for ≧20 days. Among the 5 patients who were ex-
cluded from FAS for being treated for less than 20 days,
one turned out to be in violation of the inclusion criteria
(absence of FVC before randomization to the study). The
use of FAS is considered to be acceptable since it provides
estimates of treatment effects which are likely to mirror
those observed in subsequent practice. We also performed
the analysis using the per protocol set (PPS). Since this
analysis yielded similar results to FAS, the PPS findings
were not presented. We believe that any potential bias
regarding the treatment outcome has been eliminated
in this study.
In the current study, we tested PC-SOD in a population
of patients with different diseases, including IPF and NSIP.
While including patients with different diseases in a trial
may appear unusual, the prognosis of NSIP is variable and
some patients progress to end-stage fibrosis and eventually
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NSIP has been reported to be 74 or 82.3% in previously
published studies [35,36]. Moreover, oxidative stress is
speculated to be involved in the pathogenesis of NSIP [5].
Therefore, we recruited patients with NSIP that did not
respond to steroid, as well as those with IPF.
Conclusions
PC-SOD in patients with moderate-to-severe IIP (IPF
and srf-NSIP) is well tolerated and may be a promising
agent for the improvement of biomarker levels. The
higher dose (80 mg) of PC-SOD is more effective than
the lower dose (40 mg) in reducing biomarker levels. A
larger-scale study conducted over a longer period is needed
to confirm the benefits to pulmonary function and survival
rate in patients with advanced IPF and srf-NSIP.
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